Natural resistance of human immunodeficiency virus type 2 to zidovudine (Q45466253)

14 December 2017

title

Natural resistance of human immunodeficiency virus type 2 to zidovudine (English)

1 reference

14 December 2017

4

Walid Heneine

1 reference

14 December 2017

Patrick Reid

1

1 reference

14 December 2017

Hamish MacInnes

series ordinal

2

1 reference

14 December 2017

Mian-Er Cong

series ordinal

3

1 reference

14 December 2017

J Gerardo García-Lerma

series ordinal

5

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

14 December 2017

1 reference

14 December 2017

volume

336

1 reference

14 December 2017

issue

2

1 reference

14 December 2017

page(s)

251-264

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Isolation of a new human retrovirus from West African patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Detection of Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 2 Capsid Antigens by a Monoclonal Antibody-Based Antigen Capture Assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Human immunodeficiency virus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Molecular Characterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III in the Acquired Immune Deficiency Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.03.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.03.030

1 reference

14 December 2017

1 reference